Mark E. Fraley

1.9k citations

32 papers · 1.0k · h-index 19

Impact in

Organic Chemistry top 5%
- Synthesis and biological activity
- Synthesis and Biological Evaluation
- Cyclization and Aryne Chemistry
- Chemical synthesis and alkaloids
- Synthetic Organic Chemistry Methods
- Catalytic C–H Functionalization Methods
- Multicomponent Synthesis of Heterocycles
Toxicology top 5%

Papers in

Molecular Biology 17
- DNA Repair Mechanisms 3
- Angiogenesis and VEGF in Cancer 3
Oncology 14
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 6
- Cancer-related Molecular Pathways 3

Co-authors: Andrew G. Myers (4 shared papers)Norma J. Tom (4 shared papers)Scott B. Cohen (3 shared papers)David J. Madar (3 shared papers)George D. Hartman (13 shared papers)Robert S. Rubino (3 shared papers)Kathleen Coll (7 shared papers)Kenneth A. Thomas (7 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (10 papers)Journal of the American Chemical Society (3 papers)Expert Opinion on Therapeutic Patents (2 papers)Cancer Research (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mark E. Fraley

32 papers receiving 960 citations

Peers

Countries citing papers authored by Mark E. Fraley

Since Specialization

Citations

This map shows the geographic impact of Mark E. Fraley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Fraley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Fraley more than expected).

Fields of papers citing papers by Mark E. Fraley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Fraley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Fraley. The network helps show where Mark E. Fraley may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark E. Fraley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Fraley Line = papers co-authored together Mark E. Fraley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Convergent Synthetic Route to (+)-Dynemicin A and Analogs of Wide Structural Variability Journal of the American Chemical Society ·Andrew G. Myers, Norma J. Tom, Mark E. Fraley, Scott B. Cohen, David J. Madar	1997	162
2	Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, William F. Hoffman, Robert S. Rubino, Randall W. Hungate, Andrew J. Tebben, Ruth Z. Rutledge, Rosemary C. McFall, William R. Huckle, Richard Kendall, Kathleen Coll, Kenneth A. Thomas	2002	105
3	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, Robert S. Rubino, William F. Hoffman, Scott R. Hambaugh, Kenneth L. Arrington, Randall W. Hungate, Mark T. Bilodeau, Andrew J. Tebben, Ruth Z. Rutledge, Richard Kendall, Rosemary C. McFall, William R. Huckle, Kathleen Coll, Kenneth A. Thomas	2002	79
4	Synthesis of (+)-dynemicin A and analogs of wide structural variability: establishment of the absolute configuration of natural dynemicin A Chemistry & Biology ·Andrew G. Myers, Mark E. Fraley, Norma J. Tom, Scott B. Cohen, David J. Madar	1995	70
5	Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor Journal of Pharmacology and Experimental Therapeutics ·Eric L. Moore, Mark E. Fraley, Ian M. Bell, Christopher S. Burgey, Rebecca B. White, Chi‐Chung Li, Christopher P. Regan, Andrew Danziger, Maria S. Michener, Eric D. Hostetler, Pradeep Banerjee, Christopher Salvatore	2020	51
6	An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis Molecular and Cellular Biology ·Weikang Tao, Victoria J. South, Ronald E. Diehl, Joseph P. Davide, Laura Sepp‐Lorenzino, Mark E. Fraley, Kenneth L. Arrington, Robert B. Lobell	2006	48
7	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Mark E. Fraley, Kenneth L. Arrington, Carolyn A. Buser, Patrice A. Ciecko, Kathleen Coll, Christine Fernandes, George D. Hartman, William F. Hoffman, Joseph J. Lynch, Rosemary C. McFall, Keith Rickert, Romi Singh, Sheri Smith, Kenneth A. Thomas, Bradley K. Wong	2003	43
8	Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents Expert Opinion on Investigational Drugs ·George D. Hartman, Mark E. Fraley, Mark T. Bilodeau	2002	39
9	Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorganic & Medicinal Chemistry Letters ·Christopher D. Cox, Michael J. Breslin, David B. Whitman, Paul J. Coleman, R. M. Garbaccio, Mark E. Fraley, Matthew M. Zrada, Carolyn A. Buser, Eileen S. Walsh, Kelly Hamilton, Robert B. Lobell, Weikang Tao, Marc Abrams, Vicki J. South, Hans E. Huber, Nancy E. Kohl, George D. Hartman	2007	39
10	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR Bioorganic & Medicinal Chemistry Letters ·Zhicai Wu, Mark E. Fraley, Mark T. Bilodeau, Mildred L. Kaufman, Edward S. Tasber, Adrienne E. Balitza, George D. Hartman, Kathleen Coll, Keith Rickert, Jennifer M. Shipman, Bin Shi, Laura Sepp‐Lorenzino, Kenneth A. Thomas	2004	36
11	3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts Bioorganic & Medicinal Chemistry Letters ·Edward J. Brnardic, Mark E. Fraley, R. M. Garbaccio, M. E. Layton, John M. Sanders, Chris Culberson, Marlene A. Jacobson, Brian C. Magliaro, Pete H. Hutson, Julie A. O’Brien, Sarah L. Huszar, Jason M. Uslaner, Kerry L. Fillgrove, Cuyue Tang, Yuhsin Kuo, Sylvie M. Sur, George D. Hartman	2010	30
12	Insights into the Mechanism of DNA Cleavage by Dynemicin A as Revealed by DNA-Binding and -Cleavage Studies of Synthetic Analogs Journal of the American Chemical Society ·Andrew G. Myers, Scott B. Cohen, Norma J. Tom, David J. Madar, Mark E. Fraley	1995	29
13	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert Opinion on Therapeutic Patents ·Mark E. Fraley	2009	28
14	Rapid X-ray diffraction analysis of HIV-1 protease–inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme Acta Crystallographica Section D Biological Crystallography ·S. Munshi, Z. Chen, Yihong Li, David B. Olsen, Mark E. Fraley, Randall W. Hungate, Lawrence C. Kuo	1998	27
15	Highly Convergent Route to Dynemicins of Wide Structural Variability. Enantioselective Synthesis of Quinone Imine Precursors to Natural and Nonnatural Dynemicins Journal of the American Chemical Society ·Andrew G. Myers, Mark E. Fraley, Norma J. Tom	1994	27
16	Two methods for the preparation of 2-cyclohexenones from resin-bound 1,3-cyclohexanedione Tetrahedron Letters ·Mark E. Fraley, Robert S. Rubino	1997	26
17	Property-Based Design of KDR Kinase Inhibitors Current Medicinal Chemistry ·Mark E. Fraley, William F. Hoffman, Kenneth L. Arrington, Randy W. Hungate, George D. Hartman, Rosemary C. McFall, Kathleen Coll, Keith Rickert, Kenneth A. Thomas, Georgia B. McGaughey	2004	24
18	A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth *in Vivo* Cancer Research ·Laura Sepp‐Lorenzino, Elaine Rands, Xianzhi Mao, Brett Connolly, Jennifer M. Shipman, Joanne Antanavage, Susan L. Hill, Lenora J. Davis, Stephen C. Beck, Keith Rickert, Kathleen Coll, Patrice A. Ciecko, Mark E. Fraley, William F. Hoffman, George D. Hartman, David Heimbrook, W. Wayt Gibbs, Nancy E. Kohl, Kenneth A. Thomas	2004	22
19	Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates Bioorganic & Medicinal Chemistry Letters ·Vadim Dudkin, Keith Rickert, Constantine Kreatsoulas, Cheng Wang, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yowei Yan, Mari Ikuta, Steven M. Stirdivant, Robert Drakas, Eileen S. Walsh, Kelly Hamilton, Carolyn A. Buser, Robert B. Lobell, Laura Sepp‐Lorenzino	2012	20
20	A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy Neurobiology of Disease ·Mali Cosden, Sarah Jinn, Lihang Yao, Cheryl A. Gretzula, Monika Kandebo, Dawn Toolan, Nathan G. Hatcher, Lei Ma, Wei Lemaire, Gregory C. Adam, Christine Burlein, Christina Minnick, Rose Flick, Marla L. Watt, James Mulhearn, Mark E. Fraley, Robert E. Drolet, Jacob Marcus, Sean M. Smith	2021	14

About Mark E. Fraley

Mark E. Fraley is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Cell Biology and Cellular and Molecular Neuroscience, having authored 32 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (6 papers), Microtubule and mitosis dynamics (5 papers), Migraine and Headache Studies (3 papers), Cancer-related Molecular Pathways (3 papers), DNA Repair Mechanisms (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and Quinazolinone synthesis and applications (2 papers). The work is most often cited by research in Organic Chemistry (587 citations), Toxicology (49 citations), Molecular Biology (425 citations), Cell Biology (89 citations) and Oncology (138 citations). Mark E. Fraley has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew G. Myers, Norma J. Tom, Scott B. Cohen, David J. Madar, George D. Hartman, Robert S. Rubino, Kathleen Coll, Kenneth A. Thomas, William F. Hoffman and Rosemary C. McFall. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of the American Chemical Society, Expert Opinion on Therapeutic Patents, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark E. Fraley

Impact in

Papers in i

In The Last Decade

Mark E. Fraley

Peers

Countries citing papers authored by Mark E. Fraley

Fields of papers citing papers by Mark E. Fraley

All Works

About Mark E. Fraley

Explore authors with similar magnitude of impact

Papers in